- Home
- DGII vs TNGX Comparison
DGII vs TNGX Comparison
Compare DGII & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGII
- TNGX
- Stock Information
- Founded
- DGII 1985
- TNGX 2014
- Country
- DGII United States
- TNGX United States
- Employees
- DGII N/A
- TNGX N/A
- Industry
- DGII Computer peripheral equipment
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- DGII Technology
- TNGX Health Care
- Exchange
- DGII Nasdaq
- TNGX Nasdaq
- Market Cap
- DGII 1.5B
- TNGX 1.3B
- IPO Year
- DGII N/A
- TNGX N/A
- Fundamental
- Price
- DGII $43.21
- TNGX $10.85
- Analyst Decision
- DGII Strong Buy
- TNGX Strong Buy
- Analyst Count
- DGII 5
- TNGX 7
- Target Price
- DGII $46.80
- TNGX $12.00
- AVG Volume (30 Days)
- DGII 243.2K
- TNGX 3.2M
- Earning Date
- DGII 11-12-2025
- TNGX 11-04-2025
- Dividend Yield
- DGII N/A
- TNGX N/A
- EPS Growth
- DGII 77.05
- TNGX N/A
- EPS
- DGII 1.08
- TNGX N/A
- Revenue
- DGII $430,221,000.00
- TNGX $66,501,000.00
- Revenue This Year
- DGII $8.57
- TNGX $20.41
- Revenue Next Year
- DGII $3.72
- TNGX N/A
- P/E Ratio
- DGII $39.25
- TNGX N/A
- Revenue Growth
- DGII 1.46
- TNGX 53.29
- 52 Week Low
- DGII $22.39
- TNGX $1.03
- 52 Week High
- DGII $44.79
- TNGX $11.20
- Technical
- Relative Strength Index (RSI)
- DGII 71.16
- TNGX 74.92
- Support Level
- DGII $36.89
- TNGX $9.90
- Resistance Level
- DGII $40.59
- TNGX $11.20
- Average True Range (ATR)
- DGII 2.27
- TNGX 0.74
- MACD
- DGII 0.60
- TNGX 0.32
- Stochastic Oscillator
- DGII 84.39
- TNGX 91.64
About DGII Digi International Inc.
Digi International Inc is a Minnesota corporation. The company provides business and mission-critical and Internet of Things (IoT) connectivity products and services. It has two segments: IoT Products and Services and IoT Solutions. The IoT Products and Services segment consists of distinct communications products and communication product development services. IoT Solutions segment offers wireless temperature and other environmental condition monitoring services as well as employee task management services. The company generates majority of its revenue from the IoT Products & Services segment. Geographically, the company generates majority of its revenue from its business in the United States and also has its presence in Europe, Middle East and Africa and Rest of the world.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.